202 related articles for article (PubMed ID: 25667501)
1. Cyclin I mRNA expression correlates with kinase insert domain receptor expression in human epithelial ovarian cancer.
Cybulski M; Jeleniewicz W; Nowakowski A; Stenzel-Bembenek A; Tarkowski R; Kotarski J; Stepulak A
Anticancer Res; 2015 Feb; 35(2):1115-9. PubMed ID: 25667501
[TBL] [Abstract][Full Text] [Related]
2. Sam68 is Overexpressed in Epithelial Ovarian Cancer and Promotes Tumor Cell Proliferation.
Dong L; Che H; Li M; Li X
Med Sci Monit; 2016 Sep; 22():3248-56. PubMed ID: 27623016
[TBL] [Abstract][Full Text] [Related]
3. Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer.
Cybulski M; Jarosz B; Nowakowski A; Jeleniewicz W; Kutarska E; Bednarek W; Stepulak A
Anticancer Res; 2015 Mar; 35(3):1715-21. PubMed ID: 25750333
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.
Chanakira A; Westmark PR; Ong IM; Sheehan JP
Gynecol Oncol; 2017 Apr; 145(1):167-175. PubMed ID: 28148395
[TBL] [Abstract][Full Text] [Related]
5. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis.
Sher I; Adham SA; Petrik J; Coomber BL
Int J Cancer; 2009 Feb; 124(3):553-61. PubMed ID: 19004006
[TBL] [Abstract][Full Text] [Related]
6. Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer.
Cybulski M; Jarosz B; Nowakowski A; Jeleniewicz W; Seroczyński P; Mazurek-Kociubowska M
Gynecol Oncol; 2012 Oct; 127(1):217-22. PubMed ID: 22772062
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer.
Tapia V; Gabler F; Muñoz M; Yazigi R; Paredes A; Selman A; Vega M; Romero C
Gynecol Oncol; 2011 Apr; 121(1):13-23. PubMed ID: 21236475
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer.
Paudel D; Zhou W; Ouyang Y; Dong S; Huang Q; Giri R; Wang J; Tong X
Gene; 2016 Jul; 586(1):48-55. PubMed ID: 27048832
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
10. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
Xia B; Yang S; Liu T; Lou G
Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
[TBL] [Abstract][Full Text] [Related]
11. Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
Ma M; Yu N
Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
[TBL] [Abstract][Full Text] [Related]
12. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
Han GH; Yun H; Chung JY; Kim JH; Cho H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
[TBL] [Abstract][Full Text] [Related]
13. Upregulated CDK16 Expression in Serous Epithelial Ovarian Cancer Cells.
Zhou Q; Yu Y
Med Sci Monit; 2015 Nov; 21():3409-14. PubMed ID: 26546806
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA‑455 inhibits cell proliferation and invasion of epithelial ovarian cancer by directly targeting Notch1.
Xu L; Li H; Su L; Lu Q; Liu Z
Mol Med Rep; 2017 Dec; 16(6):9777-9785. PubMed ID: 29039517
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
17. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
[TBL] [Abstract][Full Text] [Related]
20. Tumor Forkhead Box Q1 Is Elevated, Correlates with Increased Tumor Size, International Federation of Gynecology and Obstetrics Stage but Worse Overall Survival in Epithelial Ovarian Cancer Patients.
Wang X; Zhu X
Cancer Biother Radiopharm; 2022 Nov; 37(9):837-842. PubMed ID: 33761267
[No Abstract] [Full Text] [Related]
[Next] [New Search]
